drugset / Trial / NCT02651519

Sleep Quality After Stellate-ganglion Block of Patients Undergoing Breast Cancer Operation

NCT02651519 ↗

Phase 4 Completed 105 enrolled China Medical University, China
RandomizedParallel-groupTriple-blindTreatment

Summary

Stellate-ganglion block have been done safely for more than 60 years. It has proved to provide survivors of breast cancer with relief from hot flushes and sleep dysfunction with few or no side-effects. The aim of the present study is to evaluate postoperative sleep quality of patients undergoing breast cancer surgery with Stellate-ganglion block performed in the operation.

Timeline

Start
2016-01
Primary completion
2016-09
Completion
2016-09

Outcome

Met primary endpoint

paper The duration of sleep was significantly increased by 66.3 min in the ropivacaine-SGB group compared with the saline-SGB group. PMID 29043600 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Ropivacaine Other / unclassified 0.25 % —

Indications

No indication recorded.